We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current AVXL market cap is 747.71M. The company's latest EPS is USD -0.5055 and P/E is -17.17.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -11.29M | -12.52M | -14.73M | -14.34M | -13.59M |
| Net Income | -8.62M | -10.55M | -12.21M | -11.62M | -12.11M |
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 54k | 0 | 0 | 0 |
| Operating Income | -31.09M | -41.95M | -50.99M | -55.76M | -52.88M |
| Net Income | -26.28M | -37.91M | -47.98M | -47.51M | -43M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 148.07M | 144.52M | 141.54M | 135.57M | 124.04M |
| Total Liabilities | 12.5M | 9.56M | 11.75M | 15.3M | 13.13M |
| Total Equity | 135.58M | 134.96M | 129.78M | 120.26M | 110.92M |
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 34.54M | 161.62M | 152.71M | 154.39M | 135.57M |
| Total Liabilities | 7.31M | 10.8M | 10.21M | 12.53M | 15.3M |
| Total Equity | 27.24M | 150.82M | 142.49M | 141.85M | 120.26M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -7.32M | -18.97M | -24.15M | -30.81M | -12.12M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | 59k | 7.34M | 11.89M | 11.98M | 708k |
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -21.29M | -30.38M | -24.24M | -27.79M | -30.81M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | 28.35M | 153.24M | 21.29M | 29.65M | 11.98M |
| Market Cap | 747.71M |
| Price to Earnings Ratio | -17.17 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 5.59 |
| Price to Book Ratio | 6.14 |
| Dividend Yield | - |
| Shares Outstanding | 85.06M |
| Average Volume (1 week) | 836.13k |
| Average Volume (1 Month) | 986.72k |
| 52 Week Change | 63.38% |
| 52 Week High | 14.4405 |
| 52 Week Low | 3.25 |
| Spread (Intraday) | 0.04 (0.46%) |
| Company Name | Anavex Life Sciences Corporation |
| Address |
701 s carson st carson city, nevada 89701 |
| Website | https://www.anavex.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
